# Utidelone Injection Combined With Gemcitabine in First-line Chemotherapy for Unresectable Advanced Pancreatic Cancer

> **NCT05795920** · PHASE2 · UNKNOWN · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 92 (estimated)

## Conditions studied

- Pancreatic Neoplasms

## Interventions

- **DRUG:** Utidelone injection in combination with gemcitabine

## Key facts

- **NCT ID:** NCT05795920
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-08
- **Primary completion:** 2024-07-08
- **Final completion:** 2025-09-08
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2023-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05795920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05795920, "Utidelone Injection Combined With Gemcitabine in First-line Chemotherapy for Unresectable Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05795920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*